We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+8.03%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.83%
AUM
$1.09B
AUM Growth
-$31.2M
Cap. Flow
-$172M
Cap. Flow %
-15.81%
Top 10 Hldgs %
22.61%
Holding
250
New
38
Increased
46
Reduced
73
Closed
44

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 22.46%
2 Healthcare 20.78%
3 Technology 19.08%
4 Consumer Staples 8.22%
5 Industrials 5.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RGEN icon
76
Repligen
RGEN
$8.96B
$4.85M 0.44%
56,420
-322
-0.6% -$21.9K
APTV icon
77
Aptiv
APTV
$9.72B
$4.82M 0.44%
59,645
-50,808
-46% -$4.02M
GBT
78
DELISTED
Global Blood Therapeutics, Inc.
GBT
$4.65M 0.43%
88,478
+19,090
+28% +$1.1M
ARGX icon
79
argenx
ARGX
$54.4B
$4.64M 0.43%
32,774
-238
-0.7% -$30.2K
CLAR icon
80
Clarus
CLAR
$131M
$4.63M 0.42%
321,858
+85,609
+36% +$1.14M
CZR icon
81
Caesars Entertainment
CZR
$6.14B
$4.61M 0.42%
+100,000
New +$4.9M
MANT
82
DELISTED
Mantech International Corp
MANT
$4.58M 0.42%
69,496
-87,338
-56% -$5.31M
FSCT
83
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$4.55M 0.42%
134,506
-998
-0.7% -$36.7K
MC icon
84
Moelis & Co
MC
$5.07B
$4.51M 0.41%
129,187
+30,552
+31% +$1.1M
SILK
85
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$4.47M 0.41%
+92,323
New +$3.93M
KRYS icon
86
Krystal Biotech
KRYS
$9.58B
$4.44M 0.41%
110,229
-996
-0.9% -$32.6K
IMMU
87
DELISTED
Immunomedics Inc
IMMU
$4.37M 0.4%
314,912
+66,881
+27% +$1.01M
TPTX
88
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$4.35M 0.4%
+106,890
New +$3.81M
COUP
89
DELISTED
Coupa Software Incorporated
COUP
$4.31M 0.4%
+34,066
New +$3.66M
LULU icon
90
lululemon athletica
LULU
$14.2B
$4.18M 0.38%
23,218
-9,697
-29% -$1.68M
DENN
91
DELISTED
Denny's
DENN
$4.09M 0.38%
199,104
-48,101
-19% -$925K
COLM icon
92
Columbia Sportswear
COLM
$2.94B
$4.02M 0.37%
40,131
-7,983
-17% -$792K
INSM icon
93
Insmed
INSM
$28.3B
$4.02M 0.37%
157,016
+33,324
+27% +$928K
VKTX icon
94
Viking Therapeutics
VKTX
$3.88B
$4.02M 0.37%
483,951
-10,779
-2% -$92.1K
BPOP icon
95
Popular Inc
BPOP
$11.2B
$4M 0.37%
73,666
RETA
96
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.93M 0.36%
41,609
+16,278
+64% +$1.41M
CHEF icon
97
Chefs' Warehouse
CHEF
$4.5B
$3.85M 0.35%
109,880
-818
-0.7% -$26.9K
VFC icon
98
VF Corp
VFC
$5.87B
$3.84M 0.35%
+43,938
New +$3.79M
DIS icon
99
Walt Disney
DIS
$179B
$3.5M 0.32%
+25,034
New +$3.32M
ZBRA icon
100
Zebra Technologies
ZBRA
$17.4B
$3.47M 0.32%
16,584
-5,591
-25% -$1.13M

Similar funds

Nicholas Investment Partners's Q2 2019 Portfolio in Review

As of Q2 2019, Nicholas Investment Partners held 250 positions worth $1.09B, down 2.8% from $1.12B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Nicholas Investment Partners withdrew a net $172M in Q2 2019, closing 44 positions and reducing 73 holdings. Its most notable exit was Zuora, Inc., an estimated $26.2M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 22% of assets, down from 25% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Nicholas Investment Partners opened a new position in Essent Group worth $10.3M.

  • Nicholas Investment Partners's largest Q2 2019 buy was Essent Group: 219,020 shares worth $10.3M.
  • Nicholas Investment Partners added most to Pluralsight, Inc. Class A Common Stock in Q2 2019, an estimated $10.4M increase.
  • Nicholas Investment Partners's biggest Q2 2019 reduction was Wynn Resorts, cutting an estimated $24.3M.
  • Nicholas Investment Partners fully exited Zuora, Inc. in Q2 2019, selling an estimated $26.2M.
  • Nicholas Investment Partners's ten largest holdings make up 23% of its $1.09B portfolio in Q2 2019.
  • Nicholas Investment Partners opened 38 new positions and closed 44 in Q2 2019.
  • Nicholas Investment Partners's portfolio value fell 2.8% quarter-over-quarter to $1.09B.

Based on Nicholas Investment Partners's 13F filing for Q2 2019, filed 9 Aug 2019.